Welcome to ProdIgY Biotech, a pioneering force in the realm of cutting-edge biotechnology. Specializing in the research and development of IgY (Immunoglobulin Y) and hyperimmune eggs, ProdIgY stands at the forefront of innovative solutions for enhancing human and animal health. Our commitment to excellence is driven by a passion for harnessing the therapeutic potential of IgY antibodies found in eggs, opening new frontiers in the field of immunotherapy.

At ProdIgY Biotech, we leverage state-of-the-art technologies to extract and optimize the unique properties of IgY, a specialized class of antibodies prevalent in avian species. These antibodies have demonstrated remarkable efficacy in various health applications, ranging from infectious disease management to immune system modulation. Our research is dedicated to unlocking the full potential of hyperimmune eggs, paving the way for groundbreaking advancements in preventative and therapeutic healthcare solutions.

As we embark on this transformative journey, ProdIgY Biotech envisions a future where the power of nature's immune defense mechanisms is harnessed to improve the well-being of individuals worldwide. Join us in exploring the vast possibilities that IgY and hyperimmune eggs hold for the future of healthcare.


Technology: Harnessing the Power of Avian Antibodies

At the core of ProdIgY Biotech Inc.'s technology is the utilization of antibodies produced by chickens, specifically of the avian species. Chickens, like humans, generate antibodies against antigens such as bacteria, viruses, and proteins. However, the unique properties of chicken antibodies, known as IgY, set them apart from their mammalian (and human) counterparts (IgG).

Evolutionary Advantage Against Human Pathogens:

Human pathogens have evolved to adapt and evade the human immune system, often establishing themselves in the host and causing diseases. In contrast, pathogens infecting humans have not adapted to avian species, enabling chickens to mount robust immune responses against human pathogens. This distinction provides a crucial advantage in developing effective treatments against diseases caused by these microbes.

Reduced Risk of Adverse Effects:

Unlike mammalian antibodies (IgG), the administration of avian IgY to humans orally does not induce immune complex-mediated reactions, such as cell activation or inflammation. This characteristic is pivotal in minimizing adverse effects commonly associated with certain therapeutic interventions. Notably, most humans, due to the widespread consumption of eggs in their diet, have evolved to not mount immune responses to egg proteins and IgY. This unique trait opens the door to a therapeutic avenue with high efficacy and virtually no adverse effects.

Unique Oral Therapeutic Treatment Option:

The avian antibody platform offered by ProdIgY Biotech presents a distinctive oral therapeutic treatment option. With its remarkable efficacy and minimal adverse effects, this technology represents a paradigm shift in the development of treatments against several unmet diseases. By leveraging the inherent strengths of avian antibodies, ProdIgY is pioneering a new frontier in biopharmaceutical innovation, offering solutions that redefine the possibilities of oral therapeutic interventions.


Human Health Program: Harnessing the Power of Hyper Immune Egg Technology

Welcome to ProdIgY Biotech's Human Health Program, where innovation and dedication converge to redefine the landscape of healthcare. Leveraging our cutting-edge IgY and Hyper Immune Egg technology, we are committed to developing regulated human therapeutics that address critical medical challenges. Explore the milestones and ongoing initiatives in our pursuit of advancing human health:

Alcoholic Liver Disease (ALD)

Preclinical Proof of Concept (PoC): Completed:

Our Hyper Immune Egg technology has demonstrated promising results in preclinical model studies by editing of the gut microbiome in Alcoholic Liver Disease (ALD), also called Alcoholic Hepatitis (AH). This significant milestone underscores the potential of our innovative approach to bring about transformative changes in the treatment landscape.

Our groundbreaking research and findings in ALD have been recognized and published in Hepatology, contributing valuable insights to the scientific community and paving the way for future advancements (Hepatology 2023).For Full Article, Click Here.

ALD Scientific Advisory Board (SAB):

Prodigy has assembled its SAB that includes leading and world-renowned clinical researchers in ALD.

Approved Patent Claims (PCT):

The intellectual property surrounding our ALD therapeutic solution has been safeguarded with approved patent claims (PCT), ensuring the protection of our innovative technology.

Investigational New Drug (IND) Filing in 2024:

With promising preclinical results and regulatory milestones achieved, we are on track to initiate the Investigational New Drug (IND) filing process in 2024, marking a crucial step towards clinical trials.

Inflammatory Bowel Disease (IBD)

Provisional Patent Application:

Our ongoing efforts extend to addressing Inflammatory Bowel Disease (IBD), with a provisional patent application in place. This underscores our commitment to exploring novel solutions for a range of inflammatory conditions.

At ProdIgY Biotech, we are dedicated to pushing the boundaries of what is possible in human health. Our Human Health Program is driven by a passion for innovation, a commitment to scientific excellence, and a vision for a healthier future. Join us on this transformative journey as we pave the way for regulated human therapeutics that make a meaningful impact on patients' lives.


Graft vs. Host Disease (GvHD)

Approved Patent Claims (PCT):

Our innovative approach to addressing Graft vs. Host Disease (GvHD) has been recognized with approved patent claims (PCT), highlighting the uniqueness and potential impact of our therapeutic solution.

Investigational New Drug (IND) Filing in 2024:

Building on the success of our ALD program, we are poised to submit the Investigational New Drug (IND) application for our GvHD therapeutic in 2024, advancing our commitment to providing transformative solutions in human health.

Partnership Agreement with Memorial Sloan Kettering (MSK):

Prodigy and MSK have entered into a sponsored research agreement to develop product candidates for the treatment of graft versus host disease (GvHD). The program at MSK will be led by Dr. Jonathan Peled. In addition to performing the Sponsored Research, Prodigy will enter into MSK’s therapeutic-based strategic partnership program (“MSK Therapeutics Accelerator”).(Full Press Release)

Animal Programs: Transformative Solutions for Veterinary & Aquaculture Challenges

Welcome to ProdIgY Biotech's Animal Programs, where innovation meets the diverse needs of the veterinary and aquaculture industries. Our commitment to advancing natural hyper immune egg-based solutions extends to addressing critical challenges faced by the livestock and aquaculture sectors. Explore our ongoing and completed initiatives below:

Aquaculture Solutions:

White Spot Syndrome Virus (WSSV) in Shrimp

Status: Completed

Achievements: We have successfully developed transformative solutions to prevent the White Spot Syndrome Virus (WSSV) infection in shrimp, contributing to the sustainability of shrimp farming.

Intellectual Property: A patent application has been filed to safeguard our innovative approach to managing WSSV in shrimp.

Rickettsial Disease in Salmon (SRS)

Status: Ongoing

Current Focus: Our dedicated team continues to explore innovative strategies for addressing Rickettsial Disease in Salmon (SRS). Ongoing research aims to provide effective solutions for the aquaculture industry.

Intellectual Property: Stay tuned for exciting developments as we work towards patentable solutions.

Streptococcal Infection in Tilapia

Status: Paused

Current Status: While our commitment to innovation is unwavering, the Streptococcal Infection in Tilapia program is currently on hold. Our team continuously evaluates and refines our approach to ensure the most effective and responsible solutions.

Future Outlook: We remain dedicated to addressing challenges in tilapia aquaculture, and updates on the resumption of this program will be communicated in due course.

At ProdIgY Biotech, we are not just developing solutions; we are shaping the future of veterinary and aquaculture industries. Our endeavors are driven by a commitment to improving animal welfare, ensuring sustainable practices, and contributing to the overall well-being of our planet. Stay connected with us as we pave the way for transformative advancements in animal health and aquaculture management.


Veterinary Solutions:

Mastitis in Lactating Cows

Status: Completed

Achievements: Our dedicated research and development efforts have successfully addressed mastitis in lactating cows caused by MRSA strains in lactating cows. The product concept we have developed may be used either for prevention or treatment of mastitis in lactating cows. This accomplishment marks a significant milestone in enhancing animal health and productivity, and a PoC to extend the technology to other diseases in land animals.

Contact Section

Satish Chandran

Chief Executive Officer


ProdIgY Biotech Inc

719 Bradford Terrace

West Chester, PA 19382